TNF alpha and Fas mediate tissue damage and functional outcome after traumatic brain injury in mice.
Tumor necrosis factor-alpha (TNFalpha) and Fas are induced after traumatic brain injury (TBI); however, their functional roles are incompletely understood. Using controlled cortical impact (CCI) and mice deficient in TNFalpha, Fas, or both (TNFalpha/Fas-/-), we hypothesized that TNFalpha and Fas receptor mediate secondary TBI in a redundant manner. Compared with wild type (WT), TNFalpha/Fas-/- mice had improved motor performance from 1 to 4 days (P<0.05), improved spatial memory acquisition at 8 to 14 days (P<0.05), and decreased brain lesion size at 2 and 6 weeks after CCI (P<0.05). Protection in TNFalpha/Fas-/- mice from histopathological and motor deficits was reversed by reconstitution with recombinant TNFalpha before CCI, and TNFalpha-/- mice administered anti-Fas ligand antibodies had improved spatial memory acquisition versus similarly treated WT mice (P<0.05). Tumor necrosis factor-alpha/Fas-/- mice had decreased the numbers of cortical cells with plasmalemma damage at 6 h (P<0.05 versus WT), and reduced matrix metalloproteinase-9 activity in injured brain at 48 and 72 h after CCI. In immature mice subjected to CCI, genetic inhibition of TNFalpha and Fas conferred beneficial effects on histopathology and spatial memory acquisition in adulthood (both P<0.05 versus WT), suggesting that the beneficial effects of TNFalpha/Fas inhibition may be permanent. The data suggest that redundant signaling pathways initiated by TNFalpha and Fas play pivotal roles in the pathogenesis of TBI, and that biochemical mechanisms downstream of TNFalpha/Fas may be novel therapeutic targets to limit neurological sequelae in children and adults with severe TBI.
Bermpohl
Daniela
D
Neuroscience Center, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA.
You
Zerong
Z
Lo
Eng H
EH
Kim
Hyung-Hwan
HH
Whalen
Michael J
MJ
D000818:Animals; D019138:Antibodies, Blocking / Q000494:pharmacology; D001929:Brain Edema / Q000473:pathology / Q000503:physiopathology; D001930:Brain Injuries / Q000473:pathology* / Q000503:physiopathology / Q000523:psychology; D002452:Cell Count; D003071:Cognition / Q000502:physiology; D004396:Coloring Agents; D005838:Genotype; D018737:Hand Strength / Q000502:physiology; D007091:Image Processing, Computer-Assisted; D015151:Immunoblotting; D007150:Immunohistochemistry; D018782:Maze Learning / Q000502:physiology; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D009044:Motor Cortex / Q000473:pathology; D009069:Movement Disorders / Q000209:etiology / Q000503:physiopathology; D011419:Propidium; D011994:Recombinant Proteins / Q000494:pharmacology; D015398:Signal Transduction / Q000502:physiology; D014409:Tumor Necrosis Factor-alpha / Q000235:genetics / Q000502:physiology*; D019014:fas Receptor / Q000037:antagonists & inhibitors / Q000235:genetics / Q000502:physiology*
D019138:Antibodies, Blocking; D004396:Coloring Agents; C491899:Fas protein, mouse; D011994:Recombinant Proteins; D014409:Tumor Necrosis Factor-alpha; D019014:fas Receptor; D011419:Propidium